Integrating the melanoma 31-gene expression profile test to surgical oncology practice within national guideline and staging recommendations.

Integrating the melanoma 31-gene expression profile test to surgical oncology practice within national guideline and staging recommendations.

Publication date: Oct 06, 2020

Aim: Define changes in clinical management resulting from use of the prognostic 31-gene expression profile (31-GEP) test for cutaneous melanoma in a surgical oncology practice. Patients & methods: Management plans for 112 consecutively tested patients with stage I-III melanoma were evaluated for duration and number of clinical visits, blood work and imaging. Results: 31-GEP high-risk (class 2; n = 46) patients received increased management compared with low-risk (class 1; n = 66) patients. Test results were most closely associated with follow-up and imaging. Of class 1 patients, 65% received surveillance intensity within guidelines for stage I-IIA patients; 98% of class 2 patients received surveillance intensity equal to stage IIB-IV patients. Conclusion: We suggest clinical follow-up and metastatic screening be adjusted according to 31-GEP test results.

Concepts Keywords
Aim Gene expression
Blood Uveal melanoma
Gene DecisionDx-UM
Melanoma Health
Metastatic Melanoma
Surveillance Clinical medicine
Test Cancer
Medicine
RTT
III melanoma
Imaging
Clinical management

Semantics

Type Source Name
drug DRUGBANK Aspartame
pathway KEGG Melanoma
disease MESH melanoma

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *